Hi [[ session.user.profile.firstName ]]

The future of the UK pharma market: A global context

The global pharmaceutical market passes a significant milestone in 2014: reaching one trillion US dollars in total value. IMS Health forecasts the global market will see a compound average growth rate of between 4 to 7 percent in constant dollar terms to 2018, driven by two very different speed growth engines: at best low single digit value growth in the developed markets, contrasting with largely double digit growth in the power house pharmerging markets.
In this two speed world, does the UK still matter as a market to the global headquarters of the major pharmaceutical markets?

Presented by IMS Health's Sarah Rickwood and hosted by pharmaphorum's Dr Paul Tunnah, this is an opportunity to obtain informed insight into what the coming four years may mean for the UK marketplace.

Event starts 1PM UK, 2PM Europe, 8am Eastern US

In a detailed comparison of the uptake of innovation (measured as new chemical entities), in the UK relative to other country markets, IMS Health finds that while the UK market is indeed a challenging market, austerity measures mean the gap between the UK and other major European markets has reduced.

This study indicates that in the wider global context, the UK still matters for launch as one of the lead developed markets which account for the overwhelming majority of the early years of new chemical entity sales.


As this future unfurls, the UK may find that it is in the vanguard of certain key trends: the rise of digital media changing the role of patients, and the increasingly effective use of real world data to optimize healthcare. Companies which address these issues will be those that can optimize the uptake of innovative products in the UK market.
Recorded Jul 9 2014 63 mins
Your place is confirmed,
we'll send you email reminders
Presented by
Sarah Rickwood, European Director of Thought Leadership, IMS Health
Presentation preview: The future of the UK pharma market: A global context

Network with like-minded attendees

  • [[ session.user.profile.displayName ]]
    Add a photo
    • [[ session.user.profile.displayName ]]
    • [[ session.user.profile.jobTitle ]]
    • [[ session.user.profile.companyName ]]
    • [[ userProfileTemplateHelper.getLocation(session.user.profile) ]]
  • [[ card.displayName ]]
    • [[ card.displayName ]]
    • [[ card.jobTitle ]]
    • [[ card.companyName ]]
    • [[ userProfileTemplateHelper.getLocation(card) ]]
  • Channel
  • Channel profile
  • Driving positive change for patients through collaboration and education Recorded: Dec 4 2017 60 mins
    Jessica Bateman (UCF); Phyllis Greenberger (HealthyWomen); Steven Gregg (NAFC), Jenny Kite (Astellas US)
    Change Together – www.changetogether.com – will be presenting a live webinar with leading figures from the patient advocacy community, who will debate how we can drive positive change for patients through collaboration and education. This will be helpful for all advocates, as we hear and learn from our expert panel how their organizations are bringing about change.

    The key topics our expert panel will be covering are:
    – The power of collaboration
    – Educating and communicating with physicians for better patient care
    – Using social media and paid search to extend online engagement and reach
    – Effecting health policy change at a federal and state level
  • Improving commercial decisions with customer relationship network insights Recorded: Nov 28 2017 62 mins
    Megan Oh (Abbott), Leilani Latimer (Zephyr Health), Paul Tunnah (pharmaphorum)
    Networks of influence are shifting the decision-making process for life sciences companies. It is no longer enough to simply view the profile of a HCP or HCO to understand their value to your organization.

    For life sciences organizations, there is currently a gap in information, understanding, and digital access to these critical customer networks and relationships.

    Relying solely on internal knowledge, field experience or purchased data provides an analog, one-dimensional view of these networks. This limits companies from fully understanding key influencers, referral pathways, speaker and authorship networks and more, which once uncovered can significantly influence customer outreach, messaging and engagement.

    In this webinar, we’ll discuss how companies who embrace a holistic data and network analytics approach to strategic planning and execution can achieve significant competitive advantage, improved customer engagement and faster market penetration.
  • The evolution of pharma social media intelligence Recorded: Nov 23 2017 61 mins
    Paul Tunnah(Moderator); Professor Andrew Stephen (University of Oxford); Anurag Abinashi (IQVIA)
    Is your company a fully mature user of intelligence from social media, or is it still not tapping into insights?

    As shown in the consumer world, social media can be a very rich source of insights into customers and markets, and can provide early signals of new trends. Exactly the same is true for patient and health care provider insights, especially when used with other more traditional data sets.
    But understanding how to engage, and how to extract the right data to get actionable insights – and all the while complying with regulations – isn’t so straightforward.

    Life sciences companies in particular, want to put this new data source in context with its already broad range of metrics. Achieving this calls for a step-by-step progression towards social media maturity.
    pharmaphorum is working in collaboration with experts from IQVIA and Professor Andrew Stephen of Oxford University to deliver a topical debate focussed on this field, intended to provide answers to some of the conundrums the industry faces.

    An expert panel will provide practical advice and real-life examples of how pharmaceutical companies can develop maturity in social media intelligence.

    Increase your understanding of how social media can easily be used to ultimately add value

    Learn the tricks - how, when and why marketers from other sectors use social media channels to their advantage

    Hear how leading pharma organisations have embraced social media and have seen real results
  • UNLEARN. RELEARN. REIMAGINE. Smarter communications through behavioral science Recorded: Nov 22 2017 69 mins
    Andrew McConaghie, David Hogben (Complete HealthVizion), Robert Poole (Complete HealthVizion), Bjarke Ebert (Lundbeck)
    How can we create smarter, more effective communications for HCPs and patients? What can be done to challenge the status quo, apply a different mindset to communications, and deliver the best possible patient outcomes?

    In this webinar, we will discuss how multichannel strategy and behavioural science are natural partners in creating smarter, more meaningful, and more effective communications. The premise is simple: if we apply a behavioural mindset, we can determine where to focus our communications for the best effect, design the most appropriate multichannel strategy and content, and put the right metrics in place to measure success.
  • Improving outcomes through industry partnership - the Cancer Vanguard learnings Recorded: Nov 6 2017 68 mins
    Paul Tunnah(moderator)Steve Jowett(QuintilesIMS)Rob Duncombe(Christie NHS Foundation Trust)Stuart Hill(Merck)Mike Ringe(ABPI)
    The Cancer Vanguard is a bold initiative setup to take leadership in the delivery of the National Cancer Strategy – Achieving World-Class Cancer Outcomes published in 2015 with a key aim of designing and implementing new and increasingly patient centric models of care in Cancer that can benefit and be adopted by the wider national cancer system.
    In summer 2016 the Cancer Vanguard medicines optimisation team launched the ‘Pharma Challenge’ as an opportunity for the pharma and life sciences industry to identify innovative ways in which it could work in partnership with the NHS to improve the effective use of NHS resources, enhance the NHS’ understanding of the patient experience and make medicines optimisation part of routine practice. Four projects were taken forward including a partnership between the Cancer Vanguard, QuintilesIMS, Merck and uMotif,
    This unique example of partnership working across the health system is focussed on the service at large, not just the pill, and uses leading edge data analytics to analyse, benchmark and visualise the current state of the cancer pathways within the Cancer Vanguard Trusts. Furthermore it encompasses multiple aspects of the service provision ranging from patient outcomes and experiences, the flow of treatment and the usage of medicine in order to inform an evidence based and patient centric approach to service redesign and resource optimisation.
  • Pharma’s digital landscape: the evolution of multichannel strategy Recorded: Sep 19 2017 72 mins
    Paul Tunnah (Moderator) with Oksana Matviienko (Viseven), Bogdan Rakytskyi (Teva) and Chris Wade (Veeva Systems)
    Pharmaceutical marketers are increasingly native multichannel practitioners, but building an effective and efficient campaign is challenging.
    This is also because the digital landscape, and the number of options available is still rapidly evolving.
    What are the best ways to choose the right channels and the right content? And how can you plan to optimize operations further by cutting down on costs and approval times?
    This webinar brings together experts in digital marketing with case studies from a leading pharmaceutical company to keep you up to date with the latest technology and trends and provide practical advice on how to maximize your impact.
    Within one hour, you’ll discover how to optimize and streamline all content-related processes within a single platform: starting with concept development and ending with the final launch. What is more, you will find out how to reuse and repurpose your ready-made content cost-effectively, as well as save time while adapting and updating content through its whole lifecycle.
    Focus
    •How to develop best practice and a winning multichannel strategy
    •Making sure your content supports face-to-face interactions
    •Transforming the commercial teams to deliver successful digital and multichannel projects
    •How to innovate in multichannel, and the potential of future integration solutions
  • Pharma and proactive, preventative healthcare: how to use the pharmacy channel Recorded: Sep 6 2017 70 mins
    Andrew McConaghie (moderator), John Munson, Nemanja Jankovic and Nina Felton
    Across Europe, a shift towards greater prevention, earlier diagnosis and treatment is needed in order to contain the growing cost of healthcare.
    But how can healthcare systems make this transition – and how do pharmaceutical companies play a role in this, while also growing their market?
    A forthcoming webinar hosted by pharmaphorum with sponsor PHOENIX group looks at how harnessing the data and expertise of pharmacies, and via greater engagement with patients, consumers and shoppers can meet this emerging need.
    •Industry: how can pharma switch from treating a disease to earlier health management?
    The role of preventative medicine, vaccines and early diagnosis explored
    •The role of community pharmacies in prevention and health – increasing screening and diagnosis rates and facilitating appropriate medication
    •How point of sale information in pharmacies can help generate a picture of patient groups and individuals. How loyalty card schemes support OTC and consumer spending patterns, which illuminate health needs, prescription patterns and purchasing behaviour
  • How to maximise the value of digital in medtech Recorded: Jun 29 2017 64 mins
    Paul Tunnah, pharmaphorum
    With a wealth of market and regulatory changes impacting the medtech sector, it’s time for digital technology to steer the direction of your future business. This expert webinar will evaluate how to strategically embed digital within your own organisation and explore the challenges and the opportunities for transforming customer relationships, driving commercial outcomes.

    – Respond to the changing regulatory environment: how technology empowers your business
    – Build a business case for digital transformation and gain organisational support
    – Strengthen your customer relationships and improve engagement in a diverse payer landscape
    – Learn from pharma (and other industries) to find opportunities and avoid pitfalls
    – Measure impact and return on investment from digital engagement
  • Disruption and maturity: the future directions for biologics in healthcare Recorded: Jun 20 2017 65 mins
    Paul Tunnah (moderator), Angela McFarlane, Sarah Rickwood, Margaret Dolan and Timothy C. de Gavre
    A digital debate analysing the future for biologics in the UK and the factor affecting market access in this territory. Our expert panel will cover a number of key topics including:

    •Are the savings offered by biosimilars being used to innovate and take advantage of the exciting new biologic technologies or just filling in the NHS potholes?
    •Will the industry continue to invest in cutting-edge research if the UK is not prepared to fund access to it
    •In a post-Brexit world how can the UK continue to be a global leader at the cutting edge of biologics research?
  • Powering pharma’s commercial teams with market access insights Recorded: Jun 12 2017 63 mins
    Paul Tunnah, Leilani Latimer and John Stahl
    Market access is influencing drug development and commercial launch strategy more than ever before, with 85% of prescription drugs in the United States reimbursed through managed care plans. Biopharma companies must take into account a multitude of factors when considering physician prescribing behaviors, and need a more integrated "pull-through" strategy across their teams, from managed markets, to marketing, to field sales. Just as an engine needs a steady supply of fuel to run efficiently, prescriber-facing teams – the commercial engine of life sciences companies – need market access data and insights to accelerate brand success. Today, the challenge is optimizing this fuel supply, as market access and commercial teams often operate in a siloed way with regards to data, market changes and insights.
    Join a vibrant conversation with industry leaders to discuss how the industry is changing and adapting to operationalize market access pull-through for improved commercial success.
  • The future of the clinical trial – collaboration and patient centricity Recorded: May 3 2017 73 mins
    Jameisha Brown, Eric Delente, Paulo Moreira, Christine Phillips, Andrew McConaghie
    Growing patient influence combined with new technologies and the requirements of new reimbursement models means clinical research is undergoing rapid transformation. Industry is being compelled to move towards more patient centric solutions to keep up with these changes. With healthcare stakeholders in agreement that patient engagement is key to realising the value of clinical trials, regulators, sponsors, CROs, research funders and publishers are all moving towards more patient-focused models.

    With the advent of new methodologies, such as electronic data sources and medical records, recruiting patients for trials now demands extensive collaboration between patients and trial centers to effectively and efficiently run trials. The patient has never been more important.

    To mark Clinical Trials Awareness Week, pharmaphorum, in partnership with INC, will present a live webinar exploring the challenges and solutions of the current environment and how collaboration can benefit research participation, as well as the vital role the patient advocate plays in these matters.
  • Life sciences promotional content management for speed, compliance and insight Recorded: Apr 27 2017 69 mins
    David Bennett, Andrew McConaghie
    The life sciences landscape is moving at a rapid pace, which in turn is increasing the demands on marketers to create innovative, digital content faster while maintaining industry compliance.

    Veeva Systems recently conducted an annual industry study, focused on content and digital asset management within life sciences. Gleaned from the experiences and opinions of leaders across the life sciences industry, the research uncovers current practices and the industry’s need for more advanced approaches for global marketing and regulatory compliance.

    Join this webinar to hear the key insights from the survey results, and discuss key highlights with host David Bennett, VP Commercial Content Strategy Europe, Veeva.

    From this webinar you will:

    – Learn the current state of commercial content and digital asset management in life sciences promotions
    – Garner an understanding of how your organization compares to the industry
    – Understand how to accelerate your content across the digital supply chain
  • When small becomes big: orphan medicines, advances, access and affordability Recorded: Apr 10 2017 75 mins
    Alastair Kent OBE, Malcolm Qualie, Sheela Upadhyaya, Sarah Rickwood, Moderated by Paul Tunnah
    Over the past few years there has been a shift in the European pharmaceutical market landscape, with a rise in specialty medicines for diseases with narrow patient populations. Indeed, QuintilesIMS forecasts that, between 2013 and 2018, 94% of list price value growth will be in specialty medicines – with orphan drugs at the forefront of this trend.
    On 10 April 2017, QuintilesIMS, in partnership with pharmaphorum presents a unique digital debate, bringing together a panel of senior industry experts, including participants from NICE, NHS England and Genetic Alliance UK to explore the pillars of commercial success for orphan drugs in Europe in the context of changes in reimbursement processes and broader future challenges, like Brexit.
  • Unlocking the value of pharmacists to reach the right patients and consumers Recorded: Mar 29 2017 70 mins
    Pierre-Yves Boisvert, Paulien Schul, Nina Felton and Andrew McConaghie
    Pharmacists are highly trained healthcare professionals who have a deep understanding of medicines and daily contact with patients and consumers. This puts them in a unique position in terms of being able to maximise the benefits that patients get from their medicines – however, healthcare systems and pharmaceutical companies frequently overlook this potential.
    Pharmacists are especially well placed to help patients with multiple long-term conditions manage their health and medications, and pharmacist-led interventions have been shown to have a very significant impact on compliance and disease management in the community.
    We present a webinar debate in which our expert panel will discuss how pharmaceutical companies can work in collaboration with pharmacists in Europe to help patients make the most of their medicines, help generate data to prove the value of these interventions, and above all get the right medicine to the right patients and consumers.
    Join us and the PHOENIX group as we look at the practical steps needed to make this a reality. Key topics to be discussed include:
    •The challenges of identifying the right patient population across European markets
    •Understanding how pharmacists can play a greater role in patient care, e.g. improved adherence and outcomes
    •How optimum use of pharmacy level information can contribute to providing ‘real world’ evidence of treatments
  • Approval and access: Overcoming the final hurdle of drug development Recorded: Mar 10 2017 61 mins
    Professor Luca Pani, University of Miami, Angelika Joos,MSD (Europe) Inc. Ana Palma, Sobi, Belgium
    2017 is once again a year of significant change for pharma market access in Europe, with affordability on the agenda for almost every country in the region. There is a move toward greater collaboration in health technology assessment and more transparency between countries for pricing, therapeutic protocols and and details of negotiations with drug manufacturers. We also see member states working to understand the process of enabling cost-effective patient access to personalised and high-cost treatments, such as new oncology combination therapies, antibiotics and stem cell therapies, which offer the promise of efficacy in key disease areas.

    With market access being referred to as the “fourth hurdle” in drug development (beyond efficacy, safety and quality), it is vital that the requirements for both approval and access are addressed early in the process. Parallel scientific advice from HTA bodies and regulators is increasing to deliver tangible and successful strategies, but is the process smooth enough to overcome the challenges from both sides?

    pharmaphorum in partnership with DIA will be hosting an expert panel debating the best way forward for life sciences companies, payers and providers in this emerging European market access paradigm.

    Join our webinar to hear from experts in industry and healthcare discussing the challenges and solutions of access in the changing European market.
    Topics up for discussion include:
    •Integrating HTA and regulatory strategy – the best way forward
    •Regional variation and implication – how to efficiently and effectively navigate EU market access
    •Proving value – how to leverage real world evidence to meet increasing demands for observational data
    •Future proofing market access – how to improve upon evidence generation and use technology effectively and competitively
  • Taking health wearables to the next level – where is the market heading? Recorded: Dec 8 2016 63 mins
    Roberto Slepetys, Martin Pöhlchen, Gayatri Gopal, Andrew McConaghie
    With rising healthcare costs, more informed and engaged patients, and advancing technology, health wearables have seen a significant uptake in recent years. However, the full potential of health wearables has yet to be recognised and there are still challenges to be resolved. What needs to be done on the regulatory, technical and healthcare side to take health wearables to the next level?
    In this webinar, experts from the life sciences and technology industries discuss their views on the current state and future developments of health wearables, including:
    – The user perspective: perception, adoption and expectations today and tomorrow
    – The technology perspective: biggest successes and most room for improvements
    – The societal and regulatory perspective: cost and risks versus benefits and opportunities
  • The Patient Centric Launch – business insights key to success in Europe Recorded: Nov 30 2016 61 mins
    Nina Felton, Nick Cooper Larry R Smith II and Andrew McConaghie (moderator)
    Join us and PHOENIX group as we delve into the concept of current launch excellence and the role of patient insights in overcoming the multiple challenges the industry currently faces.
    Key topics to be discussed include:
    – The challenges of launching a product in Europe
    – How pharma can improve its understanding of the process through the use of business intelligence
    – How insights from new data can be applied to the process of launch excellence
    – The role of real-world data in launch strategy
    – The downstream effect of applying real-world data to product launch on patient outcomes.
  • The hepatitis C conundrum: balancing cost and affordability Recorded: Nov 22 2016 68 mins
    Ashley Pitcher, Natasha Martin, Paul Tunnah
    Working with QuintilesIMS, we present a digital debate which will offer modellling-based insights into the future of hepatitis C treatment.

    Key topics to be discussed include:
    – The burden of HCV
    – The current market landscape
    – The current patient access model and its impact on budget
    – Cost efficiencies shown by modelling
    – Cure versus lifetime treatment costs
  • Demand Assessment Research: adopting insights from behavioural economics Recorded: Nov 16 2016 52 mins
    Duncan Munro and Andrew McConaghie
    Over the past 20 years, behavioural economics has identified factors that influence and determine how people behave, including alternative decision-making pathways and many cognitive biases and heuristics. Taking account of these helps to build a clear view of how healthcare customers think and behave in relation to your product in the real world.
    This short masterclass explores ‘quantitative demand assessment research’ – what it is and how insights from behavioural economics can improve the application of this important tool in pharmaceutical market research.
    The masterclass will:
    •Introduce demand assessment research and why it is important to healthcare market research
    •Discuss how insights from behavioural economics can improve quantitative demand assessment market research
    •Highlight a range of techniques using behavioural economics that help you build a more accurate picture of your customers and market.
  • Finding a cure: Getting the best Brexit deal for Britain's life sciences Recorded: Nov 2 2016 66 mins
    Paul Tunnah, Rt Hon Stephen Dorrell, Sarah Rickwood, Lesley Galloway, Angela McFarlane, Prof. Richard Barker, OBE and more
    Senior level expert panel debate on the likely impacts of a hard v soft Brexit for life sciences companies in Britain.
Thought leadership webinars within the pharmaceutical industry
pharmaphorum provides a digital podium for communicating thought leadership and innovation within pharma. Our webinars bring together different stakeholders from across the healthcare spectrum to drive fresh thinking and novel solutions that deliver better outcomes for patients.

Embed in website or blog

Successfully added emails: 0
Remove all
  • Title: The future of the UK pharma market: A global context
  • Live at: Jul 9 2014 12:00 pm
  • Presented by: Sarah Rickwood, European Director of Thought Leadership, IMS Health
  • From:
Your email has been sent.
or close